Adaptive Biotechnologies (NASDAQ:ADPT) Insider Sharon Benzeno Sells 63,103 Shares

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) insider Sharon Benzeno sold 63,103 shares of Adaptive Biotechnologies stock in a transaction on Wednesday, March 11th. The stock was sold at an average price of $13.17, for a total transaction of $831,066.51. Following the completion of the transaction, the insider directly owned 272,751 shares of the company’s stock, valued at $3,592,130.67. The trade was a 18.79% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Adaptive Biotechnologies Stock Up 5.8%

NASDAQ ADPT traded up $0.72 during trading hours on Friday, hitting $13.17. 3,902,529 shares of the company were exchanged, compared to its average volume of 1,832,300. The stock has a market cap of $2.03 billion, a PE ratio of -32.92 and a beta of 2.19. The stock has a 50-day moving average price of $16.55 and a 200 day moving average price of $15.85. Adaptive Biotechnologies Corporation has a 52 week low of $6.68 and a 52 week high of $20.76.

Adaptive Biotechnologies (NASDAQ:ADPT) last released its quarterly earnings results on Thursday, February 5th. The company reported ($0.09) earnings per share for the quarter, beating the consensus estimate of ($0.19) by $0.10. Adaptive Biotechnologies had a negative return on equity of 46.68% and a negative net margin of 21.48%.The company had revenue of $71.68 million for the quarter, compared to analyst estimates of $59.38 million. During the same quarter in the prior year, the firm posted ($0.23) EPS. Adaptive Biotechnologies’s quarterly revenue was up 51.0% compared to the same quarter last year. As a group, sell-side analysts anticipate that Adaptive Biotechnologies Corporation will post -0.92 earnings per share for the current year.

Institutional Trading of Adaptive Biotechnologies

A number of institutional investors have recently modified their holdings of ADPT. Caitong International Asset Management Co. Ltd purchased a new position in shares of Adaptive Biotechnologies in the 4th quarter worth approximately $28,000. Sound Income Strategies LLC purchased a new stake in Adaptive Biotechnologies during the third quarter valued at approximately $30,000. EverSource Wealth Advisors LLC boosted its stake in Adaptive Biotechnologies by 197.1% in the fourth quarter. EverSource Wealth Advisors LLC now owns 2,359 shares of the company’s stock valued at $38,000 after acquiring an additional 1,565 shares in the last quarter. Assetmark Inc. grew its holdings in Adaptive Biotechnologies by 867.9% in the fourth quarter. Assetmark Inc. now owns 3,020 shares of the company’s stock worth $49,000 after purchasing an additional 2,708 shares during the last quarter. Finally, T. Rowe Price Investment Management Inc. purchased a new position in Adaptive Biotechnologies in the fourth quarter worth $51,000. 99.17% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

ADPT has been the topic of a number of research analyst reports. Weiss Ratings restated a “sell (d-)” rating on shares of Adaptive Biotechnologies in a report on Wednesday, January 21st. Piper Sandler set a $21.00 price objective on shares of Adaptive Biotechnologies in a report on Friday, February 6th. TD Cowen restated a “buy” rating on shares of Adaptive Biotechnologies in a research note on Friday, February 6th. Wall Street Zen lowered shares of Adaptive Biotechnologies from a “buy” rating to a “hold” rating in a research report on Saturday, March 7th. Finally, Morgan Stanley initiated coverage on shares of Adaptive Biotechnologies in a research note on Monday, December 1st. They set an “equal weight” rating and a $21.00 price target for the company. Seven analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $18.25.

About Adaptive Biotechnologies

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.